Milk-Derived Microvesicles for Therapeutic Encapsulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic agents face challenges such as limited bioavailability, toxicity concerns, and difficulties in encapsulating agents within natural nanoparticles like exosomes, particularly in scaling production and achieving effective dosing for disease treatment.
Innovation Solution
Milk-derived microvesicle compositions are developed, where therapeutic agents like phytochemicals and chemotherapeutics are encapsulated within milk-derived microvesicles, isolated through a series of centrifugations, and administered orally, intravenously, or intraperitoneally to treat diseases, including cancer, by modifying immune responses and reducing inflammatory cytokines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic agents are administered in large doses to achieve efficacy, then treatment effectiveness is improved, but toxicity increases
Solution Approach 1:
Milk-derived exosomes serve as intermediary carriers that encapsulate therapeutic agents, enabling controlled delivery to target cells. The exosome membrane acts as a biocompatible interface that protects the cargo from degradation while facilitating cellular uptake, thereby achieving therapeutic effects at lower doses with reduced toxicity
Solution Approach 2:
The invention changes the delivery parameter from direct administration to exosome-mediated delivery. This parameter change enables the therapeutic agent to be delivered in a controlled manner with improved bioavailability, allowing effective dosing without the toxicity associated with high-dose direct administration
2Stability of the object's composition
If natural nanoparticles like exosomes are used as carriers, then biocompatibility is improved, but encapsulation efficiency and production scalability remain difficult
Solution Approach 1:
The invention performs preliminary action by isolating and characterizing exosomes from milk sources before encapsulation. This pre-preparation step establishes a scalable starting material with known properties, enabling subsequent efficient encapsulation of therapeutic agents and facilitating large-scale production
Solution Approach 2:
Milk-derived exosomes serve as universal carriers that can encapsulate both hydrophilic and hydrophobic therapeutic agents. This multi-functionality is achieved through the exosome's lipid bilayer structure that can accommodate diverse cargo types, making the system broadly applicable while maintaining biocompatibility
3Ease of operation
If conventional delivery methods are used, then ease of administration is maintained, but bioavailability remains limited
Solution Approach 1:
The invention changes the physical parameter of the therapeutic agent by encapsulating it within exosomes. This parameter change protects the agent from degradation, improves solubility, and enhances cellular uptake, thereby significantly improving bioavailability while maintaining ease of administration through conventional routes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The milk-derived microvesicle compositions enhance bioavailability, reduce toxicity, and demonstrate significant antiproliferative and anti-inflammatory effects, offering a promising approach for treating various cancers and inflammatory disorders with improved solubility and stability of therapeutic agents.
Implementation Method 1
isolated through a series of centrifugations
Data Source
AI summary
A composition is provided that comprises a therapeutic agent encapsulated by a milk-derived microvesicle. The compositions can include therapeutic agents such as phytochemical agents or chemotherapeutic agents, while the milk-derived microvesicle can be derived from raw milk or colostrum. Further provided are methods for isolating a microvesicle that includes the steps of obtaining an amount of milk, and subjecting the milk to a series of sequential centrifugations configured to yield greater than about 300 mg of microvesicle protein per 100 ml of milk. Methods of modifying an immune response and treating a cancer in which a milk-derived microvesicle composition is administered are also provided.